L14 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:547272 CAPLUS <<LOGINID::20081211>>
DOCUMENT NUMBER: 143:103191
TITLE: Histone deacetylase inhibitors for treatment of neoplastic and inflammatory disorders
INVENTOR(S): Bressi, Jerome C.; Gangloff, Anthony R.; Jennings, Andrew J.
PATENT ASSIGNEE(S): Syrrx, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 89 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050137234	A1	20050623	US 2004-13234	20041214
WO 2005066151	A2	20050721	WO 2004-US42009	20041214
WO 2005066151	A3	20051222		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-531371P P 20031219
OTHER SOURCE(S): CASREACT 143:103191; MARPAT 143:103191
AB Histone deacetylase inhibitors and uses thereof are provided. Knowledge of the crystal structure of human histone deacetylase 8 (HDAC8) was used to guide the design of 114 chemical inhibitors. General synthetic schemes are also provided. The inhibitors are of use (no data) for treatment of various cancers, inflammation, inflammatory bowel disease, psoriasis, or transplant rejection.
IT 854714-23-1P 854714-31-1P 854714-40-2P 854714-42-4P 854714-44-6P 854714-46-8P 854714-48-0P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(histone deacetylase inhibitors for treatment of neoplastic and inflammatory disorders)
RN 854714-23-1 CAPLUS
CN 2-Propenamide, 3-[1-[(3R)-1-ethyl-3-piperidinyl]-2-phenyl-1H-benzimidazol-5-yl]-N-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 854714-31-1 CAPLUS
CN 2-Propenamide, 3-[1-[(3R)-1-ethyl-3-piperidinyl]-2-(3-fluorophenyl)-1H-benzimidazol-5-yl]-N-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 854714-40-2 CAPLUS
CN 2-Propenamide, N-hydroxy-3-(2-phenyl-1H-benzimidazol-6-yl)- (CA INDEX NAME)



RN 854714-42-4 CAPLUS
CN 2-Propenamide, N-hydroxy-3-[2-phenyl-1-(2-phenylethyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)



RN 854714-44-6 CAPLUS
CN 2-Propenamide, N-hydroxy-3-[1-[2-(4-morpholinyl)ethyl]-2-phenyl-1H-benzimidazol-5-yl]- (CA INDEX NAME)



RN 854714-46-8 CAPLUS
CN 2-Propenamide, N-hydroxy-3-[1-(1-methylethyl)-2-phenyl-1H-benzimidazol-5-yl]- (CA INDEX NAME)



RN 854714-48-0 CAPLUS
CN 2-Propenamide, N-hydroxy-3-[2-phenyl-1-[(1R)-1-phenylethyl]-1H-benzimidazol-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.